In E2-treated cells, silencing of Adora1 resulted in remarkable decrease in PCNA level compared to that in the non-silenced MCF-7 cells. the promoter of its target gene TFF1 and led to reduced TFF1 promoter activity and mRNA levels, suggesting that Adora1 is required for full transcriptional activity of ER upon E2 activation. Taken together, we demonstrated a short feed-forward loop including E2, ER, and Adora1 that favors breast cancer growth. These data suggest that Adora1 may symbolize an important target for therapeutic intervention in hormone-dependent breast malignancy. Keywords:Adora1, ER, estradiol, breast malignancy, G protein-coupled receptors, cell proliferation == Introduction == Breast malignancy is one of the most common malignancies in women, and is the second leading cause of death for women in the United States (Landiset al., 1999). The mechanisms of breast malignancy pathogenesis have been intensively analyzed, and new treatments targeting this disease have emerged. Drugs such as tamoxifen (Shenet al., 2008;Snojet al., 2008), which inhibit the ability of estrogen to activate the estrogen receptor, or aromatase inhibitors (Hayashi and Yamaguchi, 2005;Howell and Buzdar, 2005), which block aromatase enzyme activity necessary for estrogen production, are used to prevent and treat hormone-responsive breast cancer. Even with aggressive mammographic screening, adjuvant chemotherapy, and rigorous therapy for Oroxin B existing malignancy however, many of the women who develop breast malignancy will pass away from it. Identification of additional factors that contribute to breast malignancy cell proliferation may enhance our understanding of this disease and potentially facilitate the development of novel therapeutic brokers. Estrogen receptor- (ER) and its ligand estradiol (E2) play crucial roles in breast cancer growth and are important therapeutic targets for this disease (DeNardoet al., 2005;Kunet al., 2003;Pettersson and Gustafsson, 2001). There is a significant desire for understanding the mechanisms by which ER signaling is Oroxin B usually regulated in breast cancer and by using this knowledge to develop interventions to that inhibit ER signaling (Boulayet al., 2005;Fanet al., 1999;Nambaet al., 2005;Nonclercqet al., 2007). We previously reported that this adenosine A1 receptor (Adora1) is usually a novel target of ER (Linet al., 2007), thein vivoexpression of which significantly correlates with the presence of ER in breast malignancy. Adora1 is a member of the G protein-coupled receptor (GPCR) superfamily. Adora1 has been actively analyzed as a potential drug target for the treatment of fetal hypoxia, Picks disease, and for the protection of brain from traumatic brain injury and heart from ischemia-reperfusion injury (Albasanzet al., 2007;Kochaneket al., 2006;Merighiet al., 2003;Morrisonet al., 2006;Wendleret al., 2007). Based on these varied functions of Adora1, it has also been suggested that this receptor may act as a potent regulator of normal and tumor cell growth by exerting antiapoptotic and prosurvival effects. Recently, evidence has emerged that Adora1 is usually PR52B over-expressed in various breast malignancy cell lines (Mirzaet Oroxin B al., 2005). We exhibited previously that Adora1 is usually one of many target genes of ER, and we hypothesized that Adora1 may serve as a mediator of estrogen action in breast malignancy growth. Here, we decided whether Adora1 in turn regulates the transcriptional activity of ER in breast malignancy cells. Our findings suggest that Adora1 may play a dual role as a target and a regulator of ER in breast cancer cells, and a positive opinions loop between ER and Adora1 signaling may modulate malignancy cell proliferation. == Results == == Estrogen up-regulates Adora1 mRNA and protein in breast malignancy MCF-7 cells == Adora1 was identified as a novel target of ER in our previous study (Linet al., 2007). To investigate effect of estrogen on expression of Adora1 in MCF-7 cells, after immediately starvation, numerous concentrations (105, 106, Oroxin B 107, 108, 109, 1010and 1011M) of 17-estradiol (E2) were added to the medium for a period of 3 hours. Real-time PCR was performed to measure the expression of Adora1. E2 treatment significantly up-regulated Adora1 mRNA, with the largest inductions seen at 105, 108, 109M E2, and relatively lower inductions seen at 106, 107, 1010and 1011M E2 (Physique 1A). To explore the temporal response of Adora1 expression to E2 activation, MCF-7 cells were treated with 108M concentration E2 for 5 days and the level of Adora1 expression was quantified over time by real-time PCR (Physique 1B). E2 stimulated Adora1 mRNA levels as early as 60 moments. Adora1 expression reached 8-fold baseline levels at 4 hours, after which the magnitude of activation decreased gradually and disappeared by 48 hours. E2 also induced Adora1 protein levels in a time-dependent manner in MCF-7 cells (Physique 1C). A moderate E2 induction of Adora1 protein was noted at 3h. A strong E2 induction of Adora1 protein was observed at 24 h, which reached a maximum level at 48 h. The E2 antagonist ICI 182,780 reversed E2-stimulated Adora1 expression (Physique 1D)..